ABSTRACT
Keywords
Introduction
- Ruben MD
- Wu G
- Smith DF
- et al.
- Duffy JF
- Abbott SM
- Burgess HJ
- et al.
- Vadnie CA
- McClung CA.
- Walker 2nd, WH
- Bumgarner JR
- Walton JC
- et al.
- Walker 2nd, WH
- Bumgarner JR
- Walton JC
- et al.

- Walker 2nd, WH
- Bumgarner JR
- Walton JC
- et al.
- Sen A
- Hoffmann HM.
- Axelrod DE.
Prostate Cancer
Epidemiology and Cancer Incidence
- Lozano-Lorca M
- Olmedo-Requena R
- Vega-Galindo MV
- et al.
- Lozano-Lorca M
- Olmedo-Requena R
- Vega-Galindo MV
- et al.
- Hu L
- Harper A
- Heer E
- et al.
- Lozano-Lorca M
- Olmedo-Requena R
- Vega-Galindo MV
- et al.
- Hu L
- Harper A
- Heer E
- et al.
Gene Studies
- Feng D
- Xiong Q
- Zhang F
- et al.
GENE | PVALUE | AUTHOR | TYPE |
---|---|---|---|
ARNTL | <0.001 | Mocellin, S., et al. (2018) | PCa |
<0.05 | Zhu, Y., et al. (2009) | PCa | |
<0.001 | Zhou, L., et al. (2020) | RCC | |
CLOCK | 0.02 | Gu, F., et al. (2017) | PCa |
0.01 | Mocellin, S., et al. (2018) | PCa | |
CRY2 | <0.05 | Chu, L., et al. (2008) | PCa |
<0.05 | Gu, F., et al. (2017) | PCa | |
CSNK1E | <0.05 | Chu, L., et al. (2008) | PCa |
0.02 | Wendeu-Foyet, M., et al. (2019) | PCa | |
<0.05 | Zhu, Y., et al. (2009) | PCa | |
NPAS2 | <0.05 | Chu, L., et al. (2008) | PCa |
<0.0001 | Chu, L., et al. (2018) | PCa | |
0.006 | Gu, F., et al. (2017) | PCa | |
0.002 | Mocellin, S., et al. (2018) | PCa | |
0.003 | Wendeu-Foyet, M., et al. (2019) | PCa | |
<0.05 | Zhu, Y., et al. (2009) | PCa | |
NR1D1 | 0.005 | Mocellin, S., et al. (2018) | PCa |
<0.001 | Zhou, L., et al. (2020) | RCC | |
PER1 | <0.05 | Chu, L., et al. (2008) | PCa |
0.004 | Wendeu-Foyet, M., et al. (2019) | PCa | |
<0.001 | Zhou, L., et al. (2020) | RCC | |
<0.05 | Litlekalsoy, J., et al. (2016) | UCa | |
PER2 | <0.001 | Zhou, L., et al. (2020) | RCC |
<0.01 | Mazzoccoli G., et al. (2012) | RCC | |
<0.05 | Litlekalsoy, J., et al. (2016) | UCa | |
PER3 | <0.05 | Chu, L., et al. (2008) | PCa |
0.009 | Mocellin, S., et al. (2018) | PCa | |
RORA | <0.001 | Mocellin, S., et al. (2018) | PCa |
<0.001 | Zhou, L., et al. (2020) | RCC |
GENE | ASSOCIATION | PVALUE | AUTHOR | |
---|---|---|---|---|
CLOCK | Improved Overall Survival, RCC | 0.009 | Zhou, L., et al. (2020) | |
CRY1 | Fatal PCa | 0.01 | Markt, S., et al (2015) | |
0.01 | Markt, S., et al (2015) | |||
0.05 | Markt, S., et al (2015) | |||
PCa Prognosis | 0.029 | Shafi, A., et al (2021) | ||
Gleason Score ≥7 | 0.027 | Wendeu-Foyet, M., et al. (2019) | ||
Improved Overall Survival, RCC | 0.00076 | Zhou, L., et al. (2020) | ||
CRY 2 | Improved Overall Survival, RCC | <0.0001 | Zhou, L., et al. (2020) | |
NPAS2 | Biochemical Recurrence | 0.039 | Yu, C., et al. (2019) | |
Progression of Localized PCa | 0.032 | Yu, C., et al. (2019) |
Chronotherapy
- Bansal D
- Reimers MA
- Knoche EM
- Pachynski RK.
- Negoro H
- Iizumi T
- Mori Y
- et al.
- Reiter RJ
- Rosales-Corral SA
- Tan DX
- et al.
Renal Cancer
Epidemiology and Cancer Incidence
Gene Studies
Chronotherapy
- Re GL
- Santeufemia DA
- Re FL
- et al.
Bladder Cancer
Epidemiology and Cancer Incidence
Gene Studies
Chronotherapy
Conclusion
Author Contributions
Acknowledgements
References
- Effect of Circadian Rhythm on Metabolic Processes and the Regulation of Energy Balance.Ann Nutr Metab. 2019; 74: 322-330https://doi.org/10.1159/000500071
- Circadian rhythms, sleep, and metabolism.J Clin Invest. 2011; 121: 2133-2141https://doi.org/10.1172/JCI46043
- Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback.J Biol Rhythms. 2006; 21: 482-493https://doi.org/10.1177/0748730406294627
- A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine.Sci Transl Med. 2018; 10https://doi.org/10.1126/scitranslmed.aat8806
- Workshop report. Circadian rhythm sleep-wake disorders: gaps and opportunities.Sleep. 2021; 44https://doi.org/10.1093/sleep/zsaa281
- Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes.Cell. 2018; 174 (e12.): 831-842https://doi.org/10.1016/j.cell.2018.06.031
- Circadian Rhythm Disturbances in Mood Disorders: Insights into the Role of the Suprachiasmatic Nucleus.Neural Plast. 2017; 20171504507https://doi.org/10.1155/2017/1504507
- Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease.Exp Mol Med. 2015; 47: e148https://doi.org/10.1038/emm.2014.121
- Adverse metabolic and cardiovascular consequences of circadian misalignment.Proc Natl Acad Sci U S A. 2009; 106: 4453-4458https://doi.org/10.1073/pnas.0808180106
- Light Pollution and Cancer.Int J Mol Sci. 2020; 21https://doi.org/10.3390/ijms21249360
- Carcinogenicity of shift-work, painting, and fire-fighting.Lancet Oncol. 2007; 8: 1065-1066https://doi.org/10.1016/S1470-2045(07)70373-X
- Chronodisruption and cancer.Naturwissenschaften. 2008; 95: 367-382https://doi.org/10.1007/s00114-007-0335-y
- Association Between Night-Shift Work and Cancer Risk: Updated Systematic Review and Meta-Analysis.Front Oncol. 2020; 10: 1006https://doi.org/10.3389/fonc.2020.01006
- Transcriptional architecture and chromatin landscape of the core circadian clock in mammals.Science. 2012; 338: 349-354https://doi.org/10.1126/science.1226339
- Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions.Nat Genet. 2006; 38: 369-374https://doi.org/10.1038/ng1738
- CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock.Nat Neurosci. 2007; 10: 543-545https://doi.org/10.1038/nn1884
- Transcriptional architecture of the mammalian circadian clock.Nat Rev Genet. 2017; 18: 164-179https://doi.org/10.1038/nrg.2016.150
- Cancer and the Circadian Clock.Cancer Res. 2019; 79: 3806-3814https://doi.org/10.1158/0008-5472.CAN-19-0566
- Trends in Photophysiologic Concepts.Ann N Y Acad Sci. 1964; 117: 88-104https://doi.org/10.1111/j.1749-6632.1964.tb48164.x
- Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice.Int J Cancer. 2004; 111: 475-479https://doi.org/10.1002/ijc.20298
- Circadian disruption promotes tumor growth by anabolic host metabolism; experimental evidence in a rat model.BMC Cancer. 2017; 17: 625https://doi.org/10.1186/s12885-017-3636-3
- Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.PLoS One. 2010; 5: e15330https://doi.org/10.1371/journal.pone.0015330
- Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.BMC Med. 2018; 16: 20https://doi.org/10.1186/s12916-018-1010-1
- Circadian Clock and Complement Immune System-Complementary Control of Physiology and Pathology?.Front Cell Infect Microbiol. 2020; 10: 418https://doi.org/10.3389/fcimb.2020.00418
- Circadian control of the immune system.Nat Rev Immunol. 2013; 13: 190-198https://doi.org/10.1038/nri3386
- The Assessment of Circadian Rhythms Within the Immune System.Methods Mol Biol. 2021; 2130: 29-51https://doi.org/10.1007/978-1-0716-0381-9_3
- Role of core circadian clock genes in hormone release and target tissue sensitivity in the reproductive axis.Mol Cell Endocrinol. 2020; 501110655https://doi.org/10.1016/j.mce.2019.110655
- Chronotherapy of Early Colon Cancer: Advantage of Morning Dose Schedules.Cancer Inform. 2022; 2111769351211067697https://doi.org/10.1177/11769351211067697
- Impact of dosage timing of once-daily inhaled corticosteroids in asthma: A systematic review and meta-analysis.Ann Allergy Asthma Immunol. 2018; 120: 512-519https://doi.org/10.1016/j.anai.2017.12.021
- Does Timing of Antihypertensive Medication Dosing Matter?.Curr Cardiol Rep. 2020; 22: 118https://doi.org/10.1007/s11886-020-01353-7
- The optimal time of day for statin administration: a review of current evidence.Curr Opin Lipidol. 2018; 29: 340-345https://doi.org/10.1097/MOL.0000000000000524
- Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature.Clin Oncol (R Coll Radiol). 2017; 29: 231-238https://doi.org/10.1016/j.clon.2016.12.005
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33https://doi.org/10.3322/caac.21708
- Circadian genes and risk of prostate cancer: Findings from the EPICAP study.Int J Cancer. 2019; 145: 1745-1753https://doi.org/10.1002/ijc.32149
- Night Shift Work, Chronotype, Sleep Duration, and Prostate Cancer Risk: CAPLIFE Study.Int J Environ Res Public Health. 2020; 17https://doi.org/10.3390/ijerph17176300
- Social Jetlag and Prostate Cancer Incidence in Alberta's Tomorrow Project: A Prospective Cohort Study.Cancers (Basel). 2020; 12https://doi.org/10.3390/cancers12123873
- Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.Eur Urol. 2015; 67: 191-194https://doi.org/10.1016/j.eururo.2014.07.008
- Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.Cancer Res. 2009; 69: 9315-9322https://doi.org/10.1158/0008-5472.CAN-09-0648
- Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.Int J Cancer. 2017; 141: 1794-1802https://doi.org/10.1002/ijc.30883
- Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.Mol Carcinog. 2018; 57: 462-466https://doi.org/10.1002/mc.22770
- Variants in circadian genes and prostate cancer risk: a population-based study in China.Prostate Cancer Prostatic Dis. 2008; 11: 342-348https://doi.org/10.1038/sj.pcan.4501024
- Circadian clock genes and risk of fatal prostate cancer.Cancer Causes Control. 2015; 26: 25-33https://doi.org/10.1007/s10552-014-0478-z
- Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression.Cancer Cell Int. 2019; 19: 87https://doi.org/10.1186/s12935-019-0811-4
- Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.Front Immunol. 2022; 13777724https://doi.org/10.3389/fimmu.2022.777724
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13020334
- Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.Invest New Drugs. 1998; 16: 255-258https://doi.org/10.1023/a:1006195815320
- Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma.Chronobiol Int. 2016; 33: 210-219https://doi.org/10.3109/07420528.2015.1130049
- Chronoradiation Therapy for Prostate Cancer: Morning Proton Beam Therapy Ameliorates Worsening Lower Urinary Tract Symptoms.J Clin Med. 2020; 9https://doi.org/10.3390/jcm9072263
- Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.Int J Mol Sci. 2017; 18https://doi.org/10.3390/ijms18040843
- Therapeutic actions of melatonin in cancer: possible mechanisms.Integr Cancer Ther. 2008; 7: 189-203https://doi.org/10.1177/1534735408322846
- Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells.J Pineal Res. 2010; 49: 60-68https://doi.org/10.1111/j.1600-079X.2010.00767.x
- Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study.J Hypertens. 2021; 39: 1678-1688https://doi.org/10.1097/HJH.0000000000002848
- Circadian clock is associated with tumor microenvironment in kidney renal clear cell carcinoma.Aging (Albany NY). 2020; 12: 14620-14632https://doi.org/10.18632/aging.103509
- Altered expression of the clock gene machinery in kidney cancer patients.Biomed Pharmacother. 2012; 66: 175-179https://doi.org/10.1016/j.biopha.2011.11.007
- Disruption of circadian clockwork in in vivo reprogramming-induced mouse kidney tumors.Genes Cells. 2018; 23: 60-69https://doi.org/10.1111/gtc.12552
- Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies.J Transl Med. 2019; 17: 132https://doi.org/10.1186/s12967-019-1880-9
- A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer.Am J Clin Oncol. 1995; 18: 27-31https://doi.org/10.1097/00000421-199502000-00006
- Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study.Cytokine. 2020; 128154984https://doi.org/10.1016/j.cyto.2019.154984
- Treatment of muscle-invasive and advanced bladder cancer in 2020.CA Cancer J Clin. 2020; 70: 404-423https://doi.org/10.3322/caac.21631
- Night work and the risk of cancer among men.Am J Epidemiol. 2012; 176: 751-759https://doi.org/10.1093/aje/kws318
- Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes.BMC Cancer. 2016; 16: 549https://doi.org/10.1186/s12885-016-2580-y
- A circadian rhythm-related gene signature associated with tumor immunity, cisplatin efficacy, and prognosis in bladder cancer.Aging (Albany NY). 2021; 13: 25153-25179https://doi.org/10.18632/aging.203733
- High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer.Cancer Treat Rep. 1987; 71: 915-919
- Circadian regulation of DNA excision repair: implications for chrono-chemotherapy.Cell Cycle. 2009; 8: 1665-1667https://doi.org/10.4161/cc.8.11.8707
- Circadian clock protein CRY1 prevents paclitaxelinduced senescence of bladder cancer cells by promoting p53 degradation.Oncol Rep. 2021; 45: 1033-1043https://doi.org/10.3892/or.2020.7914
- Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5.J Pineal Res. 2021; 71: e12765https://doi.org/10.1111/jpi.12765
Article info
Publication history
Publication stage
In Press Journal Pre-ProofFootnotes
Conflicts of Interest Statement:
Disclaimer: The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, opinions, or policies opinions of the Uniformed Services University of the Health Sciences (USUHS), The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), the Department of Defense (DoD) or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy